Cargando…

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis

Detalles Bibliográficos
Autores principales:	Yang, Mingyang, Li, Toni, Jiang, Lihai, Wang, Yushu, Tran, Carolyn, Ao, Guangyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212623/ https://www.ncbi.nlm.nih.gov/pubmed/35728643 http://dx.doi.org/10.1016/j.jinf.2022.05.044

Ejemplares similares

Monoclonal antibody therapy improves severity and mortality of COVID-19 in organ transplant recipients: A meta-analysis
por: Yang, Mingyang, et al.
Publicado: (2022)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
por: Marcec, Robert, et al.
Publicado: (2023)

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2022)

The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: A meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2023)

The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2022)

Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis
por: Zuo, Ling, et al.
Publicado: (2022)

The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis
por: Luo, Jie, et al.
Publicado: (2023)

Regdanvimab Treatment of COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis
por: Gao, Ming, et al.
Publicado: (2023)

Correction to: Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Musculoskeletal complications of COVID-19 can contribute to its morbidity and mortality
por: Finsterer, Josef, et al.
Publicado: (2022)

Temporal changes in co-morbidities and mortality in patients hospitalized for COVID-19 in Italy
por: Angeli, Fabio, et al.
Publicado: (2020)

Mortality and Morbidity Among Persons Deprived of Liberty During the COVID-19 Pandemic in Brazil
por: Lins-Rocha, Matheus, et al.
Publicado: (2021)

Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19
por: Kim, Taeyun, et al.
Publicado: (2022)

Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
por: Park, Susin, et al.
Publicado: (2022)

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
por: Lee, Ji Yeon, et al.
Publicado: (2021)

Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Jang, Young Rock, et al.
Publicado: (2022)

The influence of corticosteroid on patients with COVID-19 infection: A meta-analysis
por: Wang, Yushu, et al.
Publicado: (2021)

Risk factors for mortality in hemodialysis patients with COVID-19: a systematic review and meta-analysis
por: Wang, Fengping, et al.
Publicado: (2021)

Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis
por: Wang, Yushu, et al.
Publicado: (2021)

Need for improving COVID-19 mortality registries: the case of Peru
por: Hernández-Vásquez, Akram, et al.
Publicado: (2021)

Comment on Evaluating Giant Hydatid Cysts: Factors Affecting Mortality and Morbidity
por: Akbulut, Sami, et al.
Publicado: (2021)

Prevalence of psychiatric morbidity following discharge after COVID-19 hospitalization
por: Wang, Philip R., et al.
Publicado: (2021)

Clinical case definition of COVID-19 and morbid obesity: Is it time to move on?
por: Valente, Marina, et al.
Publicado: (2021)

Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea
por: Hong, Sun In, et al.
Publicado: (2022)

Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Choi, Seong Jin, et al.
Publicado: (2022)

Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak
por: Lee, Chan Mi, et al.
Publicado: (2022)

Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
por: Jang, Young Rock, et al.
Publicado: (2023)

Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery
por: Aghadavoudi, Omid
Publicado: (2012)

The Rising Tide of Stimulant-Related Morbidity and Mortality Warrants Evidence-Based Treatment
por: Bahji, Anees, et al.
Publicado: (2022)

Comment on “Routine Postsurgical Anesthesia Visit to Improve 30-day Morbidity and Mortality”: An Homage to Outcome Measures Beyond Unequivocal Treatment Targets
por: Bello, Corina, et al.
Publicado: (2023)

Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis
por: Kow, Chia Siang, et al.
Publicado: (2021)

Can Correlation Between Governor's Party and COVID-19 Morbidity Be Explained by the Differences in COVID-19 Mitigation Policies in the States?
por: Shvetsova, Olga, et al.
Publicado: (2022)

A Call for Vaccine Against COVID-19: Implications for Cardiovascular Morbidity and Healthcare Utilization
por: Ho, Jamie S. Y., et al.
Publicado: (2020)

Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
por: Kwak, Yee Gyung, et al.
Publicado: (2022)

Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea
por: Lee, Ji Yeon, et al.
Publicado: (2023)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
por: Fomina, Daria S., et al.
Publicado: (2023)

Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data
por: Wang, Ying, et al.
Publicado: (2023)

Covid-19 mortality in Italian doctors
por: Manzoni, Paolo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dfr5i0u82pcoiatf7ojdujorjl